AAV Gene Therapy Constructs for Niemann-Pick Disease Type C
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no curative therapy for Niemann-Pick disease, type C (NPC), a rare and fatal neurodegenerative disorder characterized by intracellular accumulation of cholesterol and glycosphingolipids, leading to hepatosplenomegaly and severe neurological symptoms.
Innovation Solution
The development of gene therapy constructs comprising a therapeutic human nucleic acid molecule that corrects the cellular defect in NPC by using tissue-specific promoters, such as neuronal-specific calcium/calmodulin-dependent protein kinase II (CaMKII) or constitutive promoters like elongation factor 1 alpha (EF1α), to deliver NPC1 or NPC2 genes via vectors like adeno-associated viral (AAV) vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy constructs are developed to treat NPC disease, then neurological function can be improved, but the complexity of the treatment increases
Solution Approach 1:
The patent uses adeno-associated viral vectors as intermediaries to deliver the NPC1 gene to target cells. The viral vector serves as a mediator that efficiently transports the therapeutic gene across the blood-brain barrier and into neuronal cells, resolving the contradiction by providing a reliable delivery mechanism while managing the complexity through a well-characterized vector system
Solution Approach 2:
The patent employs tissue-specific promoters (such as neuronal-specific promoters) to drive expression of the NPC1 gene only in target tissues, particularly the central nervous system. This localized expression strategy improves neurological function where needed while reducing off-target effects and managing treatment complexity through precise spatial control
2Loss of substance
If tissue-specific promoters are used to deliver NPC1 genes, then cholesterol accumulation is reduced, but the manufacturing precision requirements increase
Solution Approach 1:
The patent uses tissue-specific promoters that are naturally engineered to recognize and bind only to specific cellular machinery in target tissues. This biological specificity reduces cholesterol accumulation in the CNS while minimizing the need for artificial manufacturing precision, as the promoter's natural tissue tropism provides the required selectivity
Solution Approach 2:
The patent utilizes the inherent properties of tissue-specific promoters that change their transcriptional activity based on the cellular environment. These promoters are activated only in specific tissue types through endogenous transcription factors, automatically adjusting gene expression levels according to tissue identity without requiring precise manufacturing control
3Productivity
If viral vectors are used to deliver therapeutic genes, then gene delivery efficiency is improved, but the risk of immune response increases
Solution Approach 1:
The patent uses adeno-associated viral vectors that have been engineered to separate essential viral functions from pathogenic elements. The vector contains only the minimal elements needed for gene delivery (ITRs and promoter regions) while lacking genes required for viral replication and pathogenesis, thereby maintaining high delivery efficiency while reducing immune response risk
Solution Approach 2:
The patent employs self-inactivating viral vectors that are designed to be non-replicative and transient. These vectors deliver the therapeutic gene and then naturally degrade without persisting in the host, providing efficient gene delivery while minimizing long-term immune responses through controlled, temporary presence in the target tissue
Data Source
AI summary
Provided herein are compositions and methods for the viral gene therapy (e.g., AAV-directed gene therapy) of cholesterol storage diseases or disorders, such as Niemann-Pick disease, Type C.